Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12 - Poll - MDSpire

Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12

  • By

  • Bente Langdahl

  • Yoon-Sok Chung

  • Rafal Plebanski

  • Edward Czerwinski

  • Eva Dokoupilova

  • Jerzy Supronik

  • Jan Rosa

  • Andrzej Mydlak

  • Anna Rowińska-Osuch

  • Ki-Hyun Baek

  • Audrone Urboniene

  • Robert Mordaka

  • Sohui Ahn

  • Young Hee Rho

  • Jisuk Ban

  • Richard Eastell

  • September 7, 2024

  • 0 min

Share

Original Source(s)

Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12

  • by Bente Langdahl, Yoon-Sok Chung, Rafal Plebanski, Edward Czerwinski, Eva Dokoupilova, Jerzy Supronik, Jan Rosa, Andrzej Mydlak, Anna Rowińska-Osuch, Ki-Hyun Baek, Audrone Urboniene, Robert Mordaka, Sohui Ahn, Young Hee Rho, Jisuk Ban, Richard Eastell

  • September 7, 2024

Related Content

Multimodal Progressive Fusion Model for Predicting Hip Fracture Risk in the Elderly: The MMPro-HIP Approach

Lower preoperative vitamin D levels are associated with poor clinical outcomes in elderly patients with osteoporotic vertebral compression fractures after percutaneous vertebroplasty

MiR-1a-3p/Fcgr4-dependent osteoclast activation regulates pathological bone loss